The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple surveillance systems.

Moderna (MRNA) ended the recent trading session at $26.68, demonstrating a -2.45% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.13%. At ...

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18 ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

Daniel Suárez se ha convertido en el guía turístico no oficial de todo lo relacionado con la Ciudad de México mientras NASCAR ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...